Interactions between αv-Integrin and HER2 and their role in the invasive phenotype of breast cancer cells in vitro and in rat brain

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Lal, Sangeet ^d   Kersch, Cymon ^a   Beeson, Kathleen A ^a   Wu, Y Jeffrey ^a   Muldoon, Leslie L ^a,b   Neuwelt, Edward A ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD51 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ACTIN FILAMENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; BREAST CANCER CELL LINE; CELL INFILTRATION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL STRUCTURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; PHENOTYPE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RAT; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BRAIN; BREAST TUMOR; CANCER TRANSPLANTATION; FEMALE; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION; XENOGRAFT;

ANIMALS; BRAIN; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; INTEGRIN ALPHAV; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; RATS; RECEPTOR, ERBB-2;

EID: 84942062219     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131842     Document Type: Article

References (37)

1. Patil A, Sherbet GV (2015) Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain. Cancer Letters 358: 93-99. doi: 10.1016/j.canlet.2014.12.026 PMID: 25529010.
2. Owonikoko TK, Arbiser J, Zelnak A, Shu HK, Shim H, Robin AM, et al. (2014) Current approaches to the treatment of metastatic brain tumours. Nature Reviews: Clin Oncol 11: 203-223.
3. Beasley KD, Toms SA (2011) The molecular pathobiology of metastasis to the brain: A review. Neurosurgery clinics North America 22: 7-14.
4. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22. doi: 10.1038/nrc2748 PMID: 20029421 .
5. Seguin L, Desgrosellier JS, Weis SM, Cheresh DA (2015) Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol 25: 234-240. doi: 10.1016/j.tcb.2014.12. 006 PMID: 25572304.
6. Margadant C, Monsuur HN, Norman JC, Sonnenberg A (2011) Mechanisms of integrin activation and trafficking. Curr Opin Cell Biol 23: 607-614. doi: 10.1016/j.ceb.2011.08.005 PMID: 21924601.
7. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, et al. (2001) Integrin activation controls metastasis in human breast cancer. PNAS 98: 1853-1858. PMID: 11172040.
8. Sato T, Konishi K, Maeda K, Yabushita K, Miwa A (2003) Integrin alpha v, c-erbB2 and DNA ploidy in lung metastases from colorectal cancer. Hepato-gastroenterol 50: 27-30.
9. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger RC, van der Pluijm G. (2011) Integrin alphav expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer. Am J Pathol 179: 2559-2568. doi: 10.1016/j.ajpath.2011.07.011 PMID: 21907176.
10. Vogetseder A, Thies S, Ingold B, Roth P, Weller M, Schraml P, et al. (2013) αv-Integrin isoform expression in primary human tumors and brain metastases. Int J Cancer 133: 2362-2371. doi: 10.1002/ijc. 28267 PMID: 23661241.
11. Lorger M, Krueger JS, O'Neal M, Staflin K, Felding-Habermann B (2009) Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain. Proc Natl Acad Sci U S A 106: 10666-10671. doi: 10.1073/pnas.0903035106 PMID: 19541645.
12. Liu H, Radisky DC, Yang D, Xu R, Radisky ES, Bissell MJ, et al. (2012) MYC suppresses cancer metastasis by direct transcriptional silencing of v and 3 integrin subunits. Nature Cell Biology 14: 567-574. doi: 10.1038/ncb2491 PMID: 22581054.
13. Alghisi GC, Ponsonnet L, Ruegg C (2009) The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 4: e4449. doi: 10.1371/journal.pone.0004449 PMID: 19212436.
14. Ning S, Tian J, Marshall DJ, Knox SJ (2010) Anti-{alpha}v integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res 70: 7591-7509. doi: 10.1158/0008-5472.CAN-10-1639 PMID: 20841470.
15. Wu YJ, Muldoon LL, Gahramanov S, Kraemer DF, Marshall DJ, Neuwelt EA. (2012) Targeting αv integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model. J Neuro-Oncol 110: 27-36.
16. Heidenreich A, Rawal SK, Szkarlat K, Bogdanova N, Dirix L, Stenzl A, et al. (2013) A randomized, double- blind, multicenter, phase 2 study of a human monoclonal antibody to human alpha v integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer. Annals Oncol 24: 329-336.
17. O'Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, et al. (2011) A randomised, phase II study of intetumumab, an anti-v-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer 105: 346-352. doi: 10.1038/bjc.2011.183 PMID: 21750555.
18. Kim KB, Prieto V, Joseph RW, Diwan AH, Gallick GE, Papadopoulos NE, et al. (2012) A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res 22: 294-301. PMID: 22668797.
19. Friedel P, Alexander S (2011) Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell 147: 992-1009. doi: 10.1016/j.cell.2011.11.016 PMID: 22118458.
20. Dittrich A, Gautrey H, Browell D, Tyson-Capper A (2014) The HER2 Signaling Network in Breast Cancer- Like a Spider in its Web. Journal of Mammary Gland Biology and Neoplasia: 1-18.
21. Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, et al. (2007) Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 67: 4190-4198. PMID: 17483330.
22. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, et al. (2011) Central nervous system metastases in patients with HER2-positive metastatic breast cancer: Incidence, treatment, and survival in patients from registHER. Clin Cancer Res 17: 4834-4843. doi: 10.1158/1078-0432.CCR- 10-2962 PMID: 21768129.
23. Puhalla S, Elmquist W, Freyer D, Kleinberg L, Adkins C, Lockman P, et al. (2015) Unsanctifying the sanctuary: challenges and opportunities with brain metastases. Neuro Oncol 17: 639-651. doi: 10. 1093/neuonc/nov023 PMID: 25846288.
24. Novitskaya V, Romanska H, Kordek R, Potemski P, Kusinska R, Parsons M, et al. (2014) Integrin alpha3beta1-CD151 complex regulates dimerization of ErbB2 via RhoA. Oncogene 33: 2779-2789. doi: 10.1038/onc.2013.231 PMID: 23792450 25.
25. Soung YH, Clifford JL, Chung J (2010) Crosstalk between integrin and receptor tyrosine kinase signaling in breast carcinoma progression. BMB Rep 43: 311-318. PMID: 20510013.
26. Wang SE, Xiang B, Zent R, Quaranta V, Pozzi A, Arteaga CL. (2009) Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Res 69: 475-482. doi: 10.1158/0008-5472.CAN-08-2649 PMID: 19147560.
27. Gupta P, Srivastava SK (2014) Inhibition of HER2-integrin signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression. Oncotarget 5: 1812-1828. PMID: 24729020.
28. Moore KM, Thomas GJ, Duffy SW, Warwick J, Gabe R, Chou P, et al. (2014) Therapeutic targeting of integrin αvβ6 in breast cancer. J Natl Cancer Inst 106: dju169. doi: 10.1093/jnci/dju169 PMID: 24974129.
29. Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G, et al. (2006) Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 126: 489-502. PMID: 16901783.
30. Wang H, Jin H, Beauvais DM, Rapraeger AC (2014) Cytoplasmic domain interactions of syndecan-1 and syndecan-4 with α6β4 integrin mediate human epidermal growth factor receptor (HER1 and HER2)-dependent motility and survival. J Biol Chem 289: 30318-30332. doi: 10.1074/jbc.M114. 586438 PMID: 25202019.
31. Bertelsen V, Stang E (2014) The mysterious ways of ErbB2/HER2 trafficking. Membrane 4: 424-446.
32. Sorkin A, Goh LK (2009) Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 315: 683- 696. PMID: 19278030.
33. von Schlippe M, Marshall JF, Perry P, Stone M, Zhu AJ, Hart IR. (2000) Functional interaction between E-cadherin and alphav-containing integrins in carcinoma cells. J Cell Science 113: 425-437. PMID: 10639330.
34. De Franceschi N, Hamidi H, Alanko J, Sahgal P, Ivaska J (2015) Integrin traffic-the update. J Cell Science 128: 839-852. doi: 10.1242/jcs.161653 PMID: 25663697.
35. Arjonen A, Alanko J, Veltel S, Ivaska J (2012) Distinct recycling of active and inactive β1 integrins. Traffic 13: 610-625. doi: 10.1111/j.1600-0854.2012.01327.x PMID: 22222055.
36. White DP, Caswell PT, Norman JC (2007) αvβ3 and α5β1 integrin recycling pathways dictate downstream Rho kinase signaling to regulate persistent cell migration. J Cell Biol 177: 515-525. PMID: 17485491.
37. Wickström SA, Fässler R (2011) Regulation of membrane traffic by integrin signaling. Trends Cell Biol 21: 266-273. doi: 10.1016/j.tcb.2011.02.003 PMID: 21440440.